Atopic skin signs

Are you familiar with the vicious circle of atopic dermatitis?

Atopic dermatitis (AD), a problem with disruptive symptoms involving a vicious circle.

AD comes from a disorder in the skin’s barrier function, with a destructured or altered barrier and an immune deficiency that makes it more vulnerable to possible allergens or pathogens.

Atopic skin is dry skin, as its deficient structure makes it easier for it to lose moisture. Dryness means itching, and itching means scratching. Areas of inflamed or injured skin with atopic eczema can lead to an increase in the adhesion and proliferation of bacteria (Staphylococcus aereus) that can occasionally result in complications, such as the risk of microbial superinfection.

Beneficios de Nutratopic Pro-AMP

Discover the virtuous circle of Nutratopic Pro-AMP

Nutratopic Pro-AMP combats all the symptoms, breaking the circle

Thanks to its formula with specific active substances, Nutratopic Pro-AMP is a comprehensive solution to Atopic Dermatitis, effectively combating all the symptoms and breaking the circle.

With double active protection, it restores the skin barrier by reinforcing its lipid mantle and the skin’s immune system, thanks to its formula with L-isoleucine (Pro-AMP).

It provides deep moisturisation, relieves itching and thus reduces scratching, helps to reduce inflammation and inhibits the risk of bacterial adhesion thanks to its formula with Niacinamide and Rhamnosoft.

The PRO-AMP effect in the entire Nutratopic range

Acctión Nutratopic Pro-AMP

Every product in the Nutratopic range has been formulated with a combination of active ingredients that improves symptoms associated with the outbreak of atopic dermatitis, itchiness, redness, flaking, reactivity and dryness. Paediatrically and dermatologically tested for proven efficacy and tolerance. Does not contain preservatives, perfumes or colorants.

It increases the skin's first line of defence, L-isoleucine (Pro-AMPs)

In atopic dermatitis, the pruritus and damage caused by scratching increase the inflammation, thus suppressing antimicrobial peptide (AMP) production. L-isoleucine stimulates the production of these peptides, which represent the skin’s first line of defence.

Relieves itching; boosts anti-inflammatory activity. Polidocanol, Niaciamide

Atopic dermatitis acts like a vicious circle that can be aggravated by scratching. It is therefore very important to take steps to stop the itching and prevent scratching. It is also important to reinforce anti-inflammatory activity.

Re-establishes the protective barrier. Omega 6, shea butter and glycerin

They provide the emollience required, a combination of moisturisation and protection, strengthening the lipid mantle.

It inhibits the risk of superinfection and bacterial adhesion

It inhibits the risk of superinfection and bacterial adhesion. 80%-90% of patients with AD present colonisation of the skin by Staphyloccous aureus. The severity of atopic eczema is correlated to bacterial colonisation. The effect of Rhamnosofot strengthens anti-inflammatory activity and bacterial adhesion inhibition.

Pro-AMP effect Proactive reinforcement of the skin’s immune system

It provides active double protection of the skin's defence system.

1-It reinforces the skin’s immune system thanks to L-isoleucine, increasing antimicrobial peptide (AMP) production

2-It inhibits the risk of bacterial adhesion thanks to its Rhamnosoft content.

What are AMPs and how do they work?

Antimicrobial peptides (AMPs) are an essential component of the skin’s innate immune system. They have powerful antimicrobial and antiviral activity. In atopic dermatitis, AMPs are reduced, leaving the skin more vulnerable to infection.

The effect of L-isoleucine: Pro-AMP

L-isoleucine is an essential amino acid that stimulates AMP synthesis and production, strengthening the skin’s innate immune system.

The importance of AMPs and the barrier function in atopic dermatitis

“Atopic skin can be understood as a faulty wall, which you have to supplement with all the missing or deficient parts: antimicrobial peptides (…)” Eulalia Baselga, MD - Dermatologist. Head of Dermatology Hospital de la Santa Creu i Sant Pau.

“The expression or activation of antimicrobial peptides is essential in the skin’s ability to resist bacterial infection in patients with atopic dermatitis who have a defective antimicrobial barrier”. Peter Elias, MD - Dermatologist. University of California, San Francisco. Doctor and expert in the barrier function. Creator of the “brick & mortar” concept of the corneal stratum, an example of the structure of the epidermis as a protective layer of the skin.

Acción Pro-AMP New clinical tests show that Nutratopic PRO-AMP:

Corrects the skin’s bacterial micro flora balance

Grafico Nutratopic  Pro-AMP

Corrects the skin’s bacterial micro flora balance, reducing bacteria and helping to prevent the risk of new outbreaks.

*97% of patients free of Staphylococcus aureus after applying Nutratopic Pro-AMP. After two months.1

Corrects the skin’s bacterial micro flora balance, reducing bacteria and helping to prevent the risk of new outbreaks.

*97% of patients free of Staphylococcus aureus after applying Nutratopic Pro-AMP. After two months.1

Clinically-confirmed effective reduction of atopic dermatitis symptoms

Grafico Nutratopic  Pro-AMP

Effective and long-lasting

Grafico Nutratopic  Pro-AMP

References: 1. Licari A, Marseglia A, Agostinis F, et al. Barrier Repair Therapy in Atopic Eczema: E_ects of Isoleucine, Rhamnosoft, Ceramides and Niacinamide Facial and Body Creams on Clinical, Itch and Staphylococcus aureus Skin Colonization: A Prospective Assessor-Blinded Study. Clin Pediatr Dermatol. 2016, 2:1. 2. Fabio Agostinis MD and Massimo Milano MD. Barrier Repair Therapy in Atopic Eczema: e_cay of an isoleucine, rhamnosoft and niacinamide body cream. A pilor, prosppective study. Poster 24th EADV Copenhagen 2015. 3. Marseglia A, Licari A, Agostinis F, Barcella A, Bonamonte D, Puviani M, Milani M, Marseglia G. Local rhamnosoft, ceramides and L-isoleucine in atopic eczema: a randomized, placebo controlled trial. Pediatr Allergy Immunol. 2014 May;25(3):271-5.